NASDAQ:KRYS
Krystal Biotech Inc Stock News
$163.78
+0.590 (+0.362%)
At Close: May 16, 2024
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
07:00am, Wednesday, 06'th Jul 2022
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the W
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
11:00am, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Ap
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
07:00am, Tuesday, 07'th Jun 2022
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the G
Krystal Biotech: High Potential, Buy-At-Dips Stock
11:36am, Wednesday, 25'th May 2022
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter.
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
11:30pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 s
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Monday, 09'th May 2022 Zacks Investment Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
08:15pm, Monday, 09'th May 2022 GlobeNewswire Inc.
PITTSBURGH, May 09, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational pro
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
07:00am, Tuesday, 03'rd May 2022
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chi
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
03:00pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
PITTSBURGH, March 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results from the
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
04:00pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed resul
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
11:00am, Friday, 18'th Mar 2022 GlobeNewswire Inc.
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present l
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
07:00am, Friday, 18'th Mar 2022
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present lat
Krystal Biotech reaches settlement with PeriphaGen in trade secret litigation
01:37pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Krystal Biotech (KRYS) said it reached an agreement with PeriphaGen to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020
Recap: Krystal Biotech Q4 Earnings
01:29pm, Monday, 28'th Feb 2022 Benzinga
Krystal Biotech (NASDAQ: KRYS ) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Krystal Biotech missed estimated earnings by 28.77%, reporting an EPS of … Full story available on Benzinga.com